UBS Group Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE - Get Free Report) had its price objective cut by research analysts at UBS Group from $23.00 to $21.00 in a report issued on Friday,Benzinga reports. The firm presently has a "neutral" rating on the stock. UBS Group's price objective suggests a potential upside of 0.65% from the stock's current price.

A number of other equities research analysts have also recently commented on KVUE. Piper Sandler upgraded Kenvue from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research note on Friday, January 17th. Finally, Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Kenvue Stock Up 1.4 %

NYSE KVUE traded up $0.29 on Friday, reaching $20.87. The company had a trading volume of 5,612,466 shares, compared to its average volume of 12,551,784. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $40.00 billion, a P/E ratio of 39.42, a P/E/G ratio of 2.16 and a beta of 1.45. The company's fifty day moving average is $21.54 and its 200 day moving average is $22.00. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts anticipate that Kenvue will post 1.05 earnings per share for the current fiscal year.

Institutional Trading of Kenvue

Institutional investors have recently added to or reduced their stakes in the business. AMF Tjanstepension AB boosted its holdings in Kenvue by 187.3% during the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company's stock valued at $2,787,000 after acquiring an additional 78,540 shares during the period. Mather Group LLC. grew its holdings in shares of Kenvue by 62.0% in the third quarter. Mather Group LLC. now owns 6,857 shares of the company's stock worth $159,000 after purchasing an additional 2,625 shares during the last quarter. Atomi Financial Group Inc. bought a new stake in Kenvue during the 3rd quarter valued at $212,000. Perpetual Ltd boosted its position in Kenvue by 2.6% during the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company's stock valued at $587,000 after buying an additional 652 shares during the period. Finally, Juncture Wealth Strategies LLC bought a new stake in Kenvue in the 3rd quarter worth $241,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.